Zoetis Reports Fourth Quarter and Full Year 2023 Results

Rhea-AI Summary

Zoetis Inc. (NYSE: ZTS) reports revenue of $2.2 billion for Q4 2023, growing 8%, with net income of $525 million, increasing 14%. Full-year 2023 revenue is $8.5 billion, growing 6%, with net income of $2.3 billion, increasing 11%. Full-year 2024 revenue guidance is $9.075 - $9.225 billion.

Positive

• Strong financial performance for Zoetis Inc. in Q4 2023 with revenue reaching $2.2 billion, an 8% increase compared to Q4 2022.
• Net income for Q4 2023 was $525 million, showing a significant 14% growth on a reported basis.
• Adjusted net income for Q4 2023 was $569 million, marking a 6% increase on a reported basis.
• Full-year 2023 revenue for Zoetis was $8.5 billion, growing by 6% compared to the previous year.
• Net income for the full year 2023 reached $2.3 billion, showing a remarkable 11% increase on a reported basis.
• Adjusted net income for full year 2023 was $2.5 billion, indicating a 7% growth on a reported basis.
• Zoetis provided full-year 2024 revenue guidance of $9.075 - $9.225 billion, with expected operational growth of 7% to 9%.
• The company continues to invest in innovation and growth, expanding its product portfolios and gaining approvals in various markets.

Negative

• None.

Insights

Financial Analyst

The financial results reported by Zoetis for the fourth quarter and full year of 2023 illustrate a robust performance in a challenging economic environment. The 8% increase in quarterly revenue and 6% annual growth are indicative of the company's strong market position and effective strategy execution. The reported net income growth of 14% and 15% per diluted share for the quarter, along with the full-year increases of 11% and 13%, respectively, signal a healthy profit margin and operational efficiency.

From an investment perspective, the positive growth in both top-line revenue and adjusted net income is encouraging. Zoetis's focus on innovative companion animal franchises and strategic investments in R&D and supply chain improvements are likely drivers of this growth. The revenue guidance for 2024, projecting a 7% to 9% operational growth, suggests confidence in the company's continued performance and may be a positive signal for investors.

It is also worth noting the impact of foreign exchange rates on the company's financials, as operational growth figures exclude this impact. Investors with a stake in international markets should consider currency fluctuations as a potential risk factor in their assessments.

Market Research Analyst

Zoetis's performance can be attributed to its diversified portfolio and innovation in the animal health industry. The strong growth in the companion animal products, particularly in monoclonal antibody products for OA pain, indicates a rising demand for advanced veterinary treatments. The 10% growth in U.S. companion animal product sales, driven by Librela and Solensia, reflects the potential for these products to become leading revenue generators for the company.

Internationally, the 13% reported growth in companion animal products and strategic price increases in the cattle and poultry portfolios demonstrate Zoetis's ability to capitalize on global market trends. However, the decline in sheep product sales and the decrease in the swine product portfolio in China due to market conditions highlight the variability in international markets that could affect future performance.

The expansion of the Vetscan Imagyst diagnostics platform and the approval of new vaccines and parasiticides underscore the company's commitment to growth through innovation. These developments may not only contribute to future revenue streams but also strengthen Zoetis's competitive edge in the animal health sector.

Veterinary Industry Analyst

The reported financials from Zoetis offer insight into the current state of the veterinary pharmaceuticals and diagnostics market. The success of monoclonal antibody treatments for osteoarthritis pain in companion animals, such as Librela and Solensia, reflects the industry's shift towards biologics and personalized medicine. The veterinary industry is increasingly adopting such advanced treatments, which tend to have higher price points and can drive revenue growth.

Additionally, the growth in the U.S. and international segments indicates a robust demand for animal health products across various species. The performance of the dermatology, parasiticides and diagnostics portfolios suggests that these areas remain priorities for investment and development. The approval of new products and claims, such as the expanded indications for Revolution Plus, showcases the importance of continuous innovation and regulatory achievements in sustaining market leadership.

Overall, Zoetis's financial results and strategic investments provide a positive outlook for the veterinary pharmaceutical and diagnostics industry, reflecting an environment where innovation and global market penetration are key drivers of growth.

• For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Respectively, on a Reported Basis
  • Delivers 8% Operational Growth in Revenue and 6% Operational Growth in Adjusted Net Income for Fourth Quarter 2023
  • Reports Adjusted Net Income of $569 Million, or Adjusted Diluted EPS of $1.24, for Fourth Quarter 2023
• For Full Year 2023, Zoetis Reports Revenue of $8.5 Billion, Growing 6%, and Net Income of $2.3 Billion, or $5.07 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis
  • Delivers 7% Operational Growth in Revenue and Adjusted Net Income for Full Year 2023
  • Reports Adjusted Net Income of $2.5 Billion, or Adjusted Diluted EPS of $5.32 for Full Year 2023
• Provides Full Year 2024 Revenue Guidance of $9.075 - $9.225 Billion, with Diluted EPS of $5.34 to $5.44 on a Reported Basis, or $5.74 to $5.84 on an Adjusted Basis
  • Expects to Deliver 7% to 9% Operational Growth in Revenue

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.

The company reported revenue of $2.2 billion for the fourth quarter of 2023, which was an increase of 8% compared with the fourth quarter of 2022, on both a reported and operational¹ basis. Net income for the fourth quarter of 2023 was $525 million, or $1.14 per diluted share, an increase of 14% and 15%, respectively, on a reported basis.

Adjusted net income² for the fourth quarter of 2023 was $569 million, or $1.24 per diluted share, an increase of 6% and 8%, respectively, on a reported and operational basis. Adjusted net income for the fourth quarter of 2023 excludes the net impact of $44 million for purchase accounting adjustments, acquisition-related costs and certain significant items.

For full year 2023, the company reported revenue of $8.5 billion, an increase of 6% compared with full year 2022. On an operational basis, revenue for full year 2023 increased 7%, excluding the impact of foreign currency. Net income for full year 2023 was $2.3 billion, or $5.07 per diluted share, an increase of 11% and 13%, respectively, on a reported basis.

Adjusted net income for full year 2023 was $2.5 billion, or $5.32 per diluted share, an increase of 7% and 9%, respectively, on a reported and operational basis. Adjusted net income for full year 2023 excludes the net impact of $113 million for purchase accounting adjustments, acquisition-related costs and certain significant items.

EXECUTIVE COMMENTARY

“Zoetis delivered another strong performance in 2023 thanks to our diverse portfolio across markets and species and our dedicated colleagues,” said Kristin Peck, Chief Executive Officer of Zoetis. “We grew revenue 7% operationally, driven by our innovative companion animal franchises across pain, dermatology and parasiticides. We also grew our adjusted net income 7% operationally, while continuing to support investments in R&D, supply chain, and commercial excellence capabilities that will drive our next phase of growth.”

“We are excited by the momentum of Librela in the U.S. and around the world as we work to build our next billion-dollar franchise. In addition to OA pain, we are well-positioned for growth in our other key franchises, including dermatology, parasiticides and diagnostics, and will continue to invest in solutions that will shape and expand the future of animal health. We are committed to continuing our track record of innovation and growing faster than the market, even during times of global uncertainty, and are guiding to full-year operational growth of 7% to 9% in revenue in 2024,” said Peck.

QUARTERLY HIGHLIGHTS

Zoetis organizes and manages its commercial operations across two regional segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the fourth quarter of 2023:

• Revenue in the U.S. segment was $1.2 billion, an increase of 9% compared with the fourth quarter of 2022. Sales of companion animal products increased 10%, driven by the company’s monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela^™ for dogs and Solensia^® for cats, as well as the company's flea, tick and heartworm combination product for dogs, Simparica Trio^®. Also contributing to growth in the quarter was the company's dermatology portfolio, including Apoquel^® and Cytopoint^®. Sales of livestock products increased 4% in the quarter. Growth in the poultry product portfolio was the result of favorable rotations back to certain medicated feed additives (MFAs) and the expanded use of Zoamix^®. Sales of both swine and cattle products increased in the quarter, primarily as a result of increased supply of vaccines that were limited in the same quarter the year prior.

• Revenue in the International segment was $982 million, reflecting a 9% increase on a reported basis and an increase of 8% operationally compared with the fourth quarter of 2022. Sales of companion animal products grew 13% on a reported basis and 10% operationally. Growth in the quarter was driven by the company’s monoclonal antibody products for OA pain, Librela for dogs and Solensia for cats, as well as key dermatology products, Apoquel and Cytopoint. Also contributing to growth in the quarter were Simparica^® and Simparica Trio. Sales of livestock products increased 5% on a reported basis and 7% operationally. Growth in both the company’s cattle and poultry product portfolios were driven largely by price increases across the broader international segment. The fish product portfolio grew as a result of a new vaccine launch in Norway. Sales in the sheep product portfolio declined due to unfavorable market conditions in Australia and New Zealand, while sales in the swine product portfolio decreased in China primarily due to unfavorable market conditions and a difficult comparative period versus the same quarter of the prior year.

INVESTMENTS IN GROWTH

Zoetis continues to advance innovation and care for animals across the globe. Since its last quarterly earnings announcement, Solensia (frunevetmab injection), the first injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats, received approval in Brazil. Additionally, Simparica Trio (sarolaner/moxidectin/pyrantel), the company’s triple combination oral parasiticide for dogs, was approved in China. The company expanded its Vetscan Imagyst^™ diagnostics platform in the U.S. to include new applications for artificial intelligence (AI) urine sediment analysis for dogs and cats.

On the livestock side of the business, Zoetis received approval in Mexico for Poulvac^® Procerta^® HVT-IBD-ND, a part of the company’s recombinant vector vaccine portfolio for poultry, which provides early, robust protection against Marek’s, infectious bursal and Newcastle disease viruses with one dose. Poulvac Procerta HVT-IBD, which provides protection against Marek’s and infectious bursal viruses, was approved in the EU.

Zoetis also continues to grow key product franchises through additional claim extensions in major markets. In the fourth quarter, Simparica Trio received approval in Japan for claims related to efficacy against sarcoptic and demodectic manges. Revolution^® Plus (selamectin/sarolaner), the company’s topical combination product that treats ticks, fleas, ear mites, lice and gastrointestinal worms and prevents heartworm disease in cats, received approval in the U.S. for claims related to the treatment and control of lone star tick infestations, making it the only parasiticide for cats on the market to defend against four types of ticks.

FINANCIAL GUIDANCE

Zoetis is providing full year 2024 guidance, which includes:

• Revenue between $9.075 billion to $9.225 billion (operational growth of 7% to 9%)
• Reported net income between $2.468 billion to $2.513 billion
• Adjusted net income between $2.650 billion to $2.700 billion (operational growth of 9% to 11%)
• Reported diluted EPS between $5.34 to $5.44
• Adjusted diluted EPS between $5.74 to $5.84

This guidance reflects foreign exchange rates as of late January 2024. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning.

WEBCAST & CONFERENCE CALL DETAILS

Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2023 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on February 13, 2024.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

¹ Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. 
² Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rates and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.

Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.

ZTS-COR 
ZTS-IR 
ZTS-FIN 

ZOETIS INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a) (UNAUDITED) (millions of dollars, except per share data)
	Three Months Ended December 31,								% Change			Twelve Months Ended December 31,								% Change
		2023				2022							2023				2022
Revenue	$	2,213			$	2,040			8			$	8,544			$	8,080			6
Costs and expenses:
Cost of sales		728				653			11				2,561				2,454			4
Selling, general and administrative expenses		565				514			10				2,151				2,009			7
Research and development expenses		174				148			18				614				539			14
Amortization of intangible assets		37				35			6				149				150			(1	)
Restructuring charges and certain acquisition-related costs		8				2			*				53				11			*
Interest expense		59				62			(5	)			239				221			8
Other (income)/deductions–net		(8	)			34			*				(159	)			40			*
Income before provision for taxes on income		650				592			10				2,936				2,656			11
Provision for taxes on income		127				132			(4	)			596				545			9
Net income before allocation to noncontrolling interests		523				460			14				2,340				2,111			11
Less: Net loss attributable to noncontrolling interests		(2	)			(1	)		*				(4	)			(3	)		33
Net income attributable to Zoetis	$	525			$	461			14			$	2,344			$	2,114			11
Earnings per share—basic	$	1.14			$	0.99			15			$	5.08			$	4.51			13
Earnings per share—diluted	$	1.14			$	0.99			15			$	5.07			$	4.49			13
Weighted-average shares used to calculate earnings per share
Basic		459.0				465.6							461.2				468.9
Diluted		460.1				466.8							462.3				470.4
(a) The Condensed Consolidated Statements of Income present the three and twelve months ended December 31, 2023 and 2022. Subsidiaries operating outside the U.S. are included for the three and twelve months ended November 30, 2023 and 2022.
* Calculation not meaningful.

ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data)
	Three Months Ended December 31, 2023
	GAAP Reported(a)				Purchase Accounting Adjustments				Acquisition- Related Costs(1)				Certain Significant Items(2)				Non-GAAP Adjusted(b)
Cost of sales	$	728			$	—			$	—			$	(1	)		$	727
Gross profit		1,485				—				—				1				1,486
Selling, general and administrative expenses		565				(3	)			—				—				562
Research and development expenses		174				—				—				—				174
Amortization of intangible assets		37				(32	)			—				—				5
Restructuring charges and certain acquisition-related costs		8				—				(1	)			(7	)			—
Other (income)/deductions–net		(8	)			—				—				(4	)			(12	)
Income before provision for taxes on income		650				35				1				12				698
Provision for taxes on income		127				6				1				(3	)			131
Net income attributable to Zoetis		525				29				—				15				569
Earnings per common share attributable to Zoetis–diluted		1.14				0.07				—				0.03				1.24
	Three Months Ended December 31, 2022
	GAAP Reported(a)				Purchase Accounting Adjustments				Acquisition- Related Costs(1)				Certain Significant Items(2)				Non-GAAP Adjusted(b)
Cost of sales	$	653			$	(3	)		$	—			$	—			$	650
Gross profit		1,387				3				—				—				1,390
Selling, general and administrative expenses		514				(7	)			—				—				507
Research and development expenses		148				(1	)			—				—				147
Amortization of intangible assets		35				(29	)			—				—				6
Restructuring charges and certain acquisition-related costs		2				—				(1	)			(1	)			—
Other (income)/deductions–net		34				—				—				(45	)			(11	)
Income before provision for taxes on income		592				40				1				46				679
Provision for taxes on income		132				12				—				(3	)			141
Net income attributable to Zoetis		461				28				1				49				539
Earnings per common share attributable to Zoetis–diluted		0.99				0.06				—				0.10				1.15
(a) The Condensed Consolidated Statements of Income present the three months ended December 31, 2023 and 2022. Subsidiaries operating outside the U.S. are included for the three months ended November 30, 2023 and 2022.
(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data)
	Twelve Months Ended December 31, 2023
	GAAP Reported(a)				Purchase Accounting Adjustments				Acquisition- Related Costs(1)				Certain Significant Items(2)				Non-GAAP Adjusted(b)
Cost of sales	$	2,561			$	(10	)		$	—			$	(3	)		$	2,548
Gross profit		5,983				10				—				3				5,996
Selling, general and administrative expenses		2,151				(21	)			—				—				2,130
Research and development expenses		614				(1	)			—				—				613
Amortization of intangible assets		149				(127	)			—				—				22
Restructuring charges and certain acquisition-related costs		53				—				(9	)			(44	)			—
Other (income)/deductions–net		(159	)			—				—				80				(79	)
Income before provision for taxes on income		2,936				159				9				(33	)			3,071
Provision for taxes on income		596				32				2				(12	)			618
Net income attributable to Zoetis		2,344				127				7				(21	)			2,457
Earnings per common share attributable to Zoetis–diluted		5.07				0.28				0.02				(0.05	)			5.32
	Twelve Months Ended December 31, 2022
	GAAP Reported(a)				Purchase Accounting Adjustments				Acquisition- Related Costs(1)				Certain Significant Items(2)				Non-GAAP Adjusted(b)
Cost of sales	$	2,454			$	(6	)		$	—			$	(8	)		$	2,440
Gross profit		5,626				6				—				8				5,640
Selling, general and administrative expenses		2,009				(29	)			—				—				1,980
Research and development expenses		539				(1	)			—				—				538
Amortization of intangible assets		150				(124	)			—				—				26
Restructuring charges and certain acquisition-related costs		11				—				(5	)			(6	)			—
Other (income)/deductions–net		40				—				—				(42	)			(2	)
Income before provision for taxes on income		2,656				160				5				56				2,877
Provision for taxes on income		545				40				1				(3	)			583
Net income attributable to Zoetis		2,114				120				4				59				2,297
Earnings per common share attributable to Zoetis–diluted		4.49				0.26				0.01				0.12				4.88
(a) The Condensed Consolidated Statements of Income present the twelve months ended December 31, 2023 and 2022. Subsidiaries operating outside the U.S. are included for the twelve months ended November 30, 2023 and 2022.
(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC. NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars)
(1) Acquisition-related costs include the following:
		Three Months Ended December 31,						Twelve Months Ended December 31,
			2023			2022			2023			2022
	Transaction costs(a)	$	—		$	1		$	4		$	1
	Integration costs(b)		—			—			3			4
	Restructuring charges(c)		1			—			2			—
	Total acquisition-related costs—pre-tax		1			1			9			5
	Income taxes(d)		1			—			2			1
	Total acquisition-related costs—net of tax	$	—		$	1		$	7		$	4
	(a) Transaction costs represent external costs directly related to acquiring businesses and primarily includes expenditures for banking, legal, accounting and other similar services. Included in Restructuring charges and certain acquisition-related costs.
	(b) Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes. Included in Restructuring charges and certain acquisition-related costs.
	(c) Restructuring charges represent employee termination costs, included in Restructuring charges and certain acquisition-related costs.
	(d) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

(2) Certain significant items include the following:
		Three Months Ended December 31,								Twelve Months Ended December 31,
			2023				2022				2023				2022
	Other restructuring charges and cost-reduction/productivity initiatives(a)	$	8			$	1			$	44			$	8
	Certain asset impairment charges(b)		3				41				24				47
	Net gain on sale of businesses(c)		—				—				(101	)			—
	Other		1				4				—				1
	Total certain significant items—pre-tax		12				46				(33	)			56
	Income taxes(d)		(3	)			(3	)			(12	)			(3	)
	Total certain significant items—net of tax	$	15			$	49			$	(21	)		$	59
	(a) For the three and twelve months ended December 31, 2023, primarily represents employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, primarily included in Restructuring charges and certain acquisition-related costs.
	For the twelve months ended December 31, 2022, primarily represents employee termination and exit costs associated with cost-reduction and productivity initiatives in certain international markets, included in Restructuring charges and certain acquisition-related costs, as well as product transfer costs, included in Cost of sales.
	(b) For the twelve months ended December 31, 2023, primarily represents certain asset impairment charges related to our precision animal health and diagnostics businesses, primarily included in Other (income)/deductions–net.
	For the three and twelve months ended December 31, 2022, primarily represents asset impairment charges related to customer relationships, developed technology rights and property, plant and equipment in our diagnostics, poultry, cattle and swine businesses, included in Other (income)/deductions-net.
	(c) Primarily represents a net gain on the sale of a majority interest in our pet insurance business, included in Other (income)/deductions–net.
	(d) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. Income taxes in Certain significant items also includes: For the three and twelve months ended December 31, 2023, includes a tax expense related to changes to prior years' tax positions with regard to the one-time mandatory deemed repatriation tax under the Tax Cuts and Jobs Act. For the twelve months ended December 31, 2023, also includes a benefit from the tax loss on the divestiture of Performance Livestock Analytics. For the three and twelve months ended December 31, 2022, includes a tax charge related to changes in uncertain tax positions. For the twelve months ended December 31, 2022, also includes a tax charge related to changes in valuation allowances related to impairment of certain assets.

ZOETIS INC. ADJUSTED SELECTED COSTS AND EXPENSES(a) (UNAUDITED) (millions of dollars)
		Three Months Ended December 31,								% Change
			2023				2022			Total				Foreign Exchange			Operational(b)
Adjusted cost of sales		$	727			$	650			12	%			3	%		9	%
As a percent of revenue			32.9	%			31.9	%		NA				NA			NA
Adjusted SG&A expenses			562				507			11	%			1	%		10	%
Adjusted R&D expenses			174				147			18	%			1	%		17	%
Adjusted net income attributable to Zoetis			569				539			6	%			—	%		6	%
		Twelve Months Ended December 31,								% Change
			2023				2022			Total				Foreign Exchange			Operational(b)
Adjusted cost of sales		$	2,548			$	2,440			4	%			(4	)%		8	%
As a percent of revenue			29.8	%			30.2	%		NA				NA			NA
Adjusted SG&A expenses			2,130				1,980			8	%			(1	)%		9	%
Adjusted R&D expenses			613				538			14	%			—	%		14	%
Adjusted net income attributable to Zoetis			2,457				2,297			7	%			—	%		7	%
(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition-related costs, and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.
(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.

ZOETIS INC. 2024 GUIDANCE
Selected Line Items (millions of dollars, except per share amounts)	Full Year 2024
Revenue	$9,075 to $9,225
Operational growth(a)	7% to 9%
Adjusted cost of sales as a percentage of revenue(b)	Approximately 29.5%
Adjusted SG&A expenses(b)	$2,170 to $2,220
Adjusted R&D expenses(b)	$665 to $675
Adjusted interest expense and other (income)/deductions-net(b)	Approximately $210
Effective tax rate on adjusted income(b)	20.0% to 21.0%
Adjusted diluted EPS(b)	$5.74 to $5.84
Adjusted net income(b)	$2,650 to $2,700
Operational growth(a)(c)	9% to 11%
Certain significant items and acquisition-related costs(d)	$70 - $75
The guidance reflects foreign exchange rates as of late January 2024.

Reconciliations of 2024 reported guidance to 2024 adjusted guidance follows:
(millions of dollars, except per share amounts)	Reported	Certain significant items and acquisition-related costs(d)	Purchase accounting	Adjusted(b)
Cost of sales as a percentage of revenue	~ 29.6%		~ (0.1%)	~ 29.5%
SG&A expenses	$2,191 to $2,241		~ $(21)	$2,170 to $2,220
R&D expenses	$666 to $676		~ $(1)	$665 to $675
Interest expense and other (income)/deductions	~ $240	~ $30		~ $270
Effective tax rate	20.0% to 21.0%			20.0% to 21.0%
Diluted EPS	$5.34 to $5.44	~ $0.16	~ $0.24	$5.74 to $5.84
Net income attributable to Zoetis	$2,468 to $2,513	$70 - $75	~ $112	$2,650 to $2,700
(a) Operational growth (a non-GAAP financial measure) excludes the impact of foreign exchange.
(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational growth to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.
(d) Primarily includes certain nonrecurring costs related to acquisitions and other charges.

ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars)
		Three Months Ended December 31,						% Change
			2023			2022		Total			Foreign Exchange			Operational(b)
Revenue:
Companion Animal		$	1,448		$	1,303		1	%		1	%		10	%
Livestock			745			710		5	%		(1	)%		6	%
Contract Manufacturing & Human Health			20			27		(26	)%		1	%		(27	)%
Total Revenue		$	2,213		$	2,040		8	%		—	%		8	%
U.S.
Companion Animal		$	941		$	853		10	%		—	%		10	%
Livestock			270			259		4	%		—	%		4	%
Total U.S. Revenue		$	1,211		$	1,112		9	%		—	%		9	%
International
Companion Animal		$	507		$	450		13	%		3	%		10	%
Livestock			475			451		5	%		(2	)%		7	%
Total International Revenue		$	982		$	901		9	%		1	%		8	%
Companion Animal:
Dogs and Cats		$	1,360		$	1,224		11	%		1	%		10	%
Horses			88			79		11	%		—	%		11	%
Total Companion Animal Revenue		$	1,448		$	1,303		11	%		1	%		10	%
Livestock:
Cattle		$	401		$	377		6	%		(1	)%		7	%
Swine			139			138		1	%		1	%		—	%
Poultry			127			115		10	%		(3	)%		13	%
Fish			62			61		2	%		(3	)%		5	%
Sheep and other			16			19		(16	)%		1	%		(17	)%
Total Livestock Revenue		$	745		$	710		5	%		(1	)%		6	%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.

ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars)
		Twelve Months Ended December 31,						% Change
			2023			2022		Total				Foreign Exchange			Operational(b)
Revenue:
Companion Animal		$	5,576		$	5,203		7	%			(1	)%		8	%
Livestock			2,890			2,791		4	%			(2	)%		6	%
Contract Manufacturing & Human Health			78			86		(9	)%			1	%		(10	)%
Total Revenue		$	8,544		$	8,080		6	%			(1	)%		7	%
U.S.
Companion Animal		$	3,529		$	3,341		6	%			—	%		6	%
Livestock			1,026			972		6	%			—	%		6	%
Total U.S. Revenue		$	4,555		$	4,313		6	%			—	%		6	%
International
Companion Animal		$	2,047		$	1,862		10	%			(2	)%		12	%
Livestock			1,864			1,819		2	%			(5	)%		7	%
Total International Revenue		$	3,911		$	3,681		6	%			(3	)%		9	%
Companion Animal:
Dogs and Cats		$	5,291		$	4,939		7	%			(1	)%		8	%
Horses			285			264		8	%			(1	)%		9	%
Total Companion Animal Revenue		$	5,576		$	5,203		7	%			(1	)%		8	%
Livestock:
Cattle		$	1,503		$	1,440		4	%			(3	)%		7	%
Swine			543			565		(4	)%			(2	)%		(2	)%
Poultry			524			476		10	%			(3	)%		13	%
Fish			220			212		4	%			(4	)%		8	%
Sheep and other			100			98		2	%			(6	)%		8	%
Total Livestock Revenue		$	2,890		$	2,791		4	%			(2	)%		6	%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.

ZOETIS INC. CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS (UNAUDITED) (millions of dollars)
		Three Months Ended December 31,						% Change
			2023			2022		Total				Foreign Exchange			Operational(a)
Total International		$	982.1		$	901.3		9	%			1	%		8	%
Australia			75.0			64.2		17	%			(2	)%		19	%
Brazil			117.2			96.2		22	%			7	%		15	%
Canada			71.1			65.2		9	%			(2	)%		11	%
Chile			31.4			34.8		(10	)%			1	%		(11	)%
China			64.7			91.4		(29	)%			(1	)%		(28	)%
France			40.5			35.1		15	%			8	%		7	%
Germany			54.1			44.0		23	%			8	%		15	%
Italy			33.9			25.6		32	%			9	%		23	%
Japan			38.0			36.1		5	%			(4	)%		9	%
Mexico			43.3			35.6		22	%			14	%		8	%
Spain			27.3			21.3		28	%			9	%		19	%
United Kingdom			67.9			60.3		13	%			9	%		4	%
Other Developed			138.3			114.6		21	%			4	%		17	%
Other Emerging			179.4			176.9		1	%			(13	)%		14	%
		Twelve Months Ended December 31,						% Change
			2023			2022		Total				Foreign Exchange			Operational(a)
Total International		$	3,911.2		$	3,680.8		6	%			(3	)%		9	%
Australia			322.7			288.7		12	%			(5	)%		17	%
Brazil			392.7			329.5		19	%			4	%		15	%
Canada			254.6			237.5		7	%			(5	)%		12	%
Chile			140.2			141.1		(1	)%			1	%		(2	)%
China			320.0			382.4		(16	)%			(5	)%		(11	)%
France			142.4			126.1		13	%			2	%		11	%
Germany			202.4			176.3		15	%			3	%		12	%
Italy			120.8			111.2		9	%			3	%		6	%
Japan			157.9			173.1		(9	)%			(8	)%		(1	)%
Mexico			162.4			136.2		19	%			13	%		6	%
Spain			121.6			117.8		3	%			1	%		2	%
United Kingdom			277.0			234.5		18	%			(1	)%		19	%
Other Developed			512.2			468.4		9	%			(2	)%		11	%
Other Emerging			784.3			758.0		3	%			(13	)%		16	%
(a) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.

ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars)
		Three Months Ended December 31,								% Change
			2023				2022			Total				Foreign Exchange			Operational(b)
U.S.:
Revenue		$	1,211			$	1,112			9	%			—	%		9	%
Cost of sales			255				216			18	%			—	%		18	%
Gross profit			956				896			7	%			—	%		7	%
Gross margin			78.9	%			80.6	%
Operating expenses			184				187			(2	)%			—	%		(2	)%
Other (income)/deductions-net			6				(12	)		*				*			*
U.S. Earnings		$	766			$	721			6	%			—	%		6	%
International:
Revenue		$	982			$	901			9	%			1	%		8	%
Cost of sales			322				274			18	%			1	%		17	%
Gross profit			660				627			5	%			—	%		5	%
Gross margin			67.2	%			69.6	%
Operating expenses			165				155			6	%			1	%		5	%
Other (income)/deductions-net			1				2			*				*			*
International Earnings		$	494			$	470			5	%			—	%		5	%
Total Reportable Segments		$	1,260			$	1,191			6	%			—	%		6	%
Other business activities(c)			(142	)			(109	)		30	%
Reconciling Items:
Corporate(d)			(320	)			(302	)		6	%
Purchase accounting adjustments(e)			(35	)			(40	)		(13	)%
Acquisition-related costs(f)			(1	)			(1	)		—	%
Certain significant items(g)			(12	)			(46	)		(74	)%
Other unallocated(h)			(100	)			(101	)		(1	)%
Total Earnings(i)		$	650			$	592			10	%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.
(c) Other business activities reflect the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition and the impact of divestiture-related gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
* Calculation not meaningful.

ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars)
		Twelve Months Ended December 31,								% Change
			2023				2022			Total				Foreign Exchange			Operational(b)
U.S.:
Revenue		$	4,555			$	4,313			6	%			—	%		6	%
Cost of sales			900				803			12	%			—	%		12	%
Gross profit			3,655				3,510			4	%			—	%		4	%
Gross margin			80.2	%			81.4	%
Operating expenses			786				765			3	%			—	%		3	%
Other (income)/deductions-net			6				(18	)		*				*			*
U.S. Earnings		$	2,863			$	2,763			4	%			—	%		4	%
International:
Revenue		$	3,911			$	3,681			6	%			(3	)%		9	%
Cost of sales			1,234				1,083			14	%			(5	)%		19	%
Gross profit			2,677				2,598			3	%			(2	)%		5	%
Gross margin			68.4	%			70.6	%
Operating expenses			638				611			4	%			(4	)%		8	%
Other (income)/deductions-net			2				(3	)		*				*			*
International Earnings		$	2,037			$	1,990			2	%			(2	)%		4	%
Total Reportable Segments		$	4,900			$	4,753			3	%			(1	)%		4	%
Other business activities(c)			(496	)			(424	)		17	%
Reconciling Items:
Corporate(d)			(1,042	)			(1,073	)		(3	)%
Purchase accounting adjustments(e)			(159	)			(160	)		(1	)%
Acquisition-related costs(f)			(9	)			(5	)		80	%
Certain significant items(g)			33				(56	)		*
Other unallocated(h)			(291	)			(379	)		(23	)%
Total Earnings(i)		$	2,936			$	2,656			11	%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.
(c) Other business activities reflect the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition and the impact of divestiture-related gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
* Calculation not meaningful.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212731050/en/

Media:

Jenielle Alonso

1-973-945-4333 (o)

jenielle.alonso@zoetis.com

Laura Panza

1-973-975-5176 (o)

laura.panza@zoetis.com

Investor:

Steve Frank

1-973-822-7141 (o)

steve.frank@zoetis.com

Nick Soonthornchai

1-973-443-2792 (o)

nick.soonthornchai@zoetis.com

Source: Zoetis Inc.

FAQ

What was Zoetis' revenue for the fourth quarter of 2023?

Zoetis reported revenue of $2.2 billion for the fourth quarter of 2023, growing 8% compared to the same period in 2022.

What was the net income for Zoetis in the fourth quarter of 2023?

The net income for Zoetis in the fourth quarter of 2023 was $525 million, showing a 14% increase.

What was the full-year revenue for Zoetis in 2023?

Zoetis reported full-year revenue of $8.5 billion for 2023, growing by 6% compared to the previous year.

What is Zoetis' revenue guidance for full year 2024?

Zoetis provided revenue guidance of $9.075 - $9.225 billion for full year 2024, with expected operational growth of 7% to 9%.